Background {#Sec1}
==========

Sphingosine-1-phosphate (S1P) is a product of sphingomyelin (SM) metabolism. It is present in most eukaryotic organisms. S1P regulates cell function both intracellularly and by binding to extracellular receptors \[[@CR1]\]. As an extracellular mediator, S1P binds to a family of G-protein-coupled receptors named S1P(1)-S1P(5) and has multiple physiological effects \[[@CR2]\]. In the immune system, cell surface S1P(1) receptors transduce the rapid, transient effects of extracellular S1P on T- and B-lymphocyte trafficking, promote early T-cell migration to tissue sites of immune responses, and regulate T-cell proliferation and secretion of numerous cytokines \[[@CR1],[@CR3]\]. S1P receptors are also found on all cell types in the CNS, and the effects of S1P on neurons \[[@CR4]\], astrocytes \[[@CR5],[@CR6]\], oligodendrocytes \[[@CR7]\], and microglia \[[@CR8],[@CR9]\] are highly cell-type specific. For example, S1P is a chemoattractant for neural precursor cells and is proposed to direct migration of neurons to sites of injury \[[@CR10]\]. Additionally, S1P \[[@CR7]\] or synthetic ligands of S1P receptors \[[@CR11],[@CR12]\] interact with neurotrophin-3 to promote survival of oligodendrocytes.

S1P is abundant in plasma where it is bound to high-density lipoproteins and albumin \[[@CR13]\]. Recently we have shown that plasma gelsolin, an actin-binding PIP~2~-regulated protein, can also act as a universal carrier or scavenger of S1P, and its function may include interference with S1P actions \[[@CR14]\]. Such an interaction may be of importance in settings where the concentrations of both substances change over their homeostatic ranges. Multiple sclerosis (MS), a chronic immune-mediated inflammatory disease of the CNS, seems to be one example of such a condition \[[@CR15]\]. In the CSF of patients with MS, S1P and gelsolin concentrations showed a tendency to increase and decrease, respectively, when compared to other non-inflammatory neurological disorders \[[@CR15]\]. An inflammatory reaction accompanied by central nervous system (CNS) infections such as tick-borne encephalitis (TBE) or Lyme neuroborreliosis (LNB), also results in blood and cerebrospinal fluid (CSF) alterations in plasma gelsolin \[[@CR15]\]. TBE, a systemic infection with RNA virus leads to the development of an acute meningitis and encephalitis, characterized by swelling of the brain due to inflammation \[[@CR16]\]. Even though TBE can be prevented by active immunization, it is still very common in some regions of the world, such as Central Europe, and currently no specific treatment is known \[[@CR17],[@CR18]\]. We hypothesize that TBE may result in an alteration of S1P concentration in the blood and CSF of patients, and in such a case modulation of S1P cellular effects may be used to develop new treatment strategies. FTY720P, a S1P receptor modulator, was found to be highly effective in the treatment of MS \[[@CR19]\], and its immunomodulatory activity may be potentially beneficial in other CNS inflammatory conditions.

Materials and methods {#Sec2}
=====================

Materials {#Sec3}
---------

S1P (S9666) was purchased from Sigma Aldrich (St Louis, Missouri, United States). (S)- fingolimod phosphate (FTY720P; B-0721) was purchased from Echelon Biosciences Inc. (Salt Lake City, Utah, United States). Recombinant human plasma gelsolin (rhGSN) was obtained from Biogen-Idec Inc (Cambridge, Massachusetts, United States). Stock solutions of S1P were prepared in 0.3 M NaOH, since pH strongly affects the aggregation behavior of S1P \[[@CR20]\]. Various concentrations of S1P were prepared by mixing its sonicated stock solution; 10 minutes, at room temperature (RT) with buffer required for a particular experiment.

Specimen collections {#Sec4}
--------------------

Human blood and CSF specimen collection was performed in the Department of Neurology and Department of Infectious Diseases and Neuroinfections at the Medical University of Białystok (Poland). Blood was collected in heparinized syringes and centrifuged at 1,500 g for 5 minutes at 4°C. The protocol for this study was approved by the Ethics Committee for Research on Humans, Medical University of Białystok (approval number: R-I-002/382/2012). At the time of patient recruitment, written consent was obtained from all subjects. All individuals were undergoing lumbar puncture for diagnostic purposes, and most of the TBE patients received a second lumbar puncture 10 to 12 days later to monitor the course of the disease. Following lumbar punctures, CSF cells were counted, and the rest of the material (after centrifugation: 2,000 g for 10 minutes), along with plasma samples, were frozen and kept at −80°C.

Clinical and laboratory characteristics of the patient groups are given in Table [1](#Tab1){ref-type="table"}. Briefly, all TBE patients were divided into the following groups: without and with glucocorticosteroids (GCs) treatment (+G), from whom the CSF and plasma were collected at admission (TBE-I/TBE + G-I; patients at time of admission and first lumbar puncture without or with GCs treatment respectively) and patients from whom the CSF and plasma samples were collected after 10 to 12 days of treatment (TBE-II/TBE + G-II; patients after 10 to 12 days of hospitalization, non-treated or treated with GCs, respectively). Diagnosis of TBE was confirmed by detection of anti-TBE virus antibodies in the serum and CSF by ELISA (Virion-SERION kit, SERION ELISA classic TBE Virus IgG/IgM,Würzburg, Germany). All TBE patients were given symptomatic treatment (analgesics, antipyretics, and intravenous rehydration). Additionally, patients in poor general condition (fever above 39°C and seizures or disturbances of consciousness (Glasgow Coma Scale score \<12 points)) were treated with glucocorticosteroid (dexamethasone 12 to 16 mg daily), which was given intravenously during a period of four to six days.Table 1**Clinical and laboratory characteristics of the patient groupsClinical groupTotal numberAgeCSF(Females)(Years)QALBTotal protein (μg/ml)LymphocytesTBE-I**with GCs treatment21(10)43.7 ± 16.212.1 ± 1.4851 ± 121105 ± 15.1without GCs treatment24(11)829 ± 12993 ± 12.1**TBE-II**40.7 ± 16.911.3 ± 1.7with GCs treatment19(10)811 ± 12876 ± 23.4without GCs treatment44.2 ± 12.811.6 ± 1.3784 ± 12276 ± 14.120(9)**LNB**39.1 ± 16.710.8 ± 1.3782 ± 15248.2 ± 9.318(7)46.5 ± 10.39.8 ± 1.1**MS**22(16)37.2 ± 13.46.5 ± 0.9435 ± 1635.7 ± 4.6**Control**Idiopathic cephalgia21(14)43.6 ± 21.46.1 ± 0.5414 ± 1443.7 ± 1.9Idiopathic (Bell's) facial nerve palsy16(10)45.2 ± 18.86.7 ± 1.1375 ± 1834.1 ± 1.2QALB = albumin concentration in CSF: albumin concentration in blood. CSF -- cerebrospinal fluid, TBE-I -- tick borne encephalitis before treatment, TBE-II -- tick borne encephalitis after 10 to 12 days of treatment, LNB -- Lyme neuroborreliosis, MS -- multiple sclerosis, GCs -- glucocorticosteroids.

LNB was diagnosed according to the European Federation of Neurological Societies criteria \[[@CR21]\]. In all our LNB patients the diagnosis was 'definite neuroborreliosis' and all of them suffered from meningitis, which is a typical clinical manifestation of early LNB. The ELISA method (Borrelia recombinant IgG/IgM ELISA, Vienna, Austria) and immunoblotting (LINE Virotech, Rüsselsheim, Germany) were used to detect antibodies against *Borrelia burgdorferi* in serum and CSF of LNB patients. MS patients included in the study were in the process of MS diagnosis, and their EDSS (Expanded Disability Status Scale) scores were between 0.5 and 4.0 (1.7 ± 0.9). Finally, they were diagnosed according to McDonald's criteria \[[@CR22]\] as relapsing-remitting MS. At the time of lumbar puncture none of the MS patients was treated with steroids or any disease-modifying drugs. Control patients without infection were diagnosed with conditions such as idiopathic cephalgia and idiopathic Bell's facial nerve palsy, in which standard CSF diagnostic tests show no abnormalities.

Evaluation of sphingosine-1-phosphate in blood plasma and cerebrospinal fluid samples {#Sec5}
-------------------------------------------------------------------------------------

S1P concentration was measured by the method described in Min *et al*. \[[@CR23]\]. Briefly, acidified methanol and internal standard (30 pmol of C~17~-S1P, Avanti Polar Lipids, Inc., Alabaster, USA) were added to 250 μl of plasma or CSF, and the samples were ultrasonicated in ice-cold water for one minute. Lipids were then extracted by the addition of chloroform, 1 M NaCl, and 3 N NaOH. The alkaline aqueous phase containing S1P was transferred to a fresh tube. The residual S1P in the chloroform phase was re-extracted twice with methanol/1 M NaCl (1:1, v/v) solution, and then all the aqueous fractions were combined. The amount of S1P was determined indirectly after dephosphorylation to sphingosine, with the use of alkaline phosphatase (bovine intestinal mucosa, Fluka, Milwaukee, Washington, United States). To improve the extraction yield of released sphingosine, chloroform was carefully placed at the bottom of the reaction tubes. The chloroform fraction containing the dephosphorylated sphingoid base was washed three times with alkaline water (pH adjusted to 10.0 with ammonium hydroxide) and then evaporated under a nitrogen stream. The dried lipid residues were re-dissolved in ethanol, converted to their o-phthalaldehyde derivatives, and analyzed using an HPLC system (ProStar, Varian Inc. Walnut Creek, USA) equipped with a fluorescence detector and a C18 reversed-phase column (OmniSpher 5, 4.6150 mm, Varian Inc. Walnut Creek, USA). The isocratic eluent composition of acetonitrile/water (9:1, v/v) and a flow rate of 1 ml/min were used. Column temperature was maintained at 33°C by use of a column oven (Varian Inc. Walnut Creek, USA).

Cell culture study {#Sec6}
------------------

Mixed cortical cultures were obtained from prenatal rats and maintained for 14 days, or until confluence was reached, in Neurobasal™ media supplemented with 0.4 M GlutaMax and B27 (50× dilution) (Life Technologies, 3175 Staley Road, Grand Island, NY 14072, USA) at 37°C and 5% CO~2~. Neuronal cells were removed through a series of trypsinizations, and the remaining astrocytes were maintained at 37°C and 5% CO2 in DMEM + GlutaMax (Life Technologies, 3175 Staley Road, Grand Island, NY 14072, USA) supplemented with 5% fetal bovine serum. The purity of astrocyte cultures was 80% or more, as determined by immunofluorescence staining for glial fibrillary acidic protein \[[@CR24],[@CR25]\]. In all experiments, the medium was changed to serum-free 6 to 12 hours prior to S1P, GSN, or FTY720P addition. Rat astrocytes were treated for 8 hours, fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 and stained for F-actin with Phalloidin-FITC (Life Technologies, 3175 Staley Road, Grand Island, NY 14072, USA). Microscopic evaluation was performed using a Leica microscope (Leica Microsystems Inc., 1700 Leider Lane Buffalo Grove, IL 60089, USA) (40× objective) and images captured with a Hamamatsu camera (Hamamatsu, Eastern Regional Office, 250 Wood Avenue Middlesex, NJ 08846, USA). To evaluate GSN and FTY720P effects on interleukin-6 (IL-6) release from rat astrocytes, cells were activated for 8 hours. Cell-free supernatants were collected by centrifugation at 5,000 × g for 5 minutes and stored at −80°C until cytokine determination. IL-6 was measured using a sandwich enzyme-linked immunosorbent assay (ELISA Kits, DRG Interleukin-6 (human) Marburg, Germany), according to the manufacturer's instructions.

Statistical analysis {#Sec7}
--------------------

Data are reported as a mean ± SE (standard error) or SD (standard deviation). Data analysis was performed using one-way analysis of variance (ANOVA) tests with a *post-hoc* Bonferroni analysis test. Differences between means were evaluated using the Student's t-test, with *P* \<0.05 being taken as the level of significance.

Results and discussion {#Sec8}
======================

Using HPLC methods, we found that the average S1P concentration in plasma of TBE (451.0 ± 21.8 nM) and LNB (538.0 ± 30.5 nM) patients was significantly higher (*P* \<0.001) than in control subjects (383 ± 23.3 nM) (Figure [1](#Fig1){ref-type="fig"}). There were no differences between average S1P concentration in the plasma of control and MS patients. Average S1P concentrations in the CSF of patients with inflammatory diseases of the CNS (MS 1.71 ± 0.29 nM, LNB 1.5 ± 0.14 nM, TBE 1.74 ± 0.14 nM) were also significantly higher (*P* \<0.001) compared to the control group (0.72 ± 0.16 nM). These results are in close agreement with our previous study in which we showed an intrathecal increase of S1P in early stage MS \[[@CR26]\]. They also confirm our preliminary finding of an increase of S1P concentration in lymphocytic meningitis \[[@CR14]\]. Comparing S1P concentration at different stages of TBE, as shown in Figure [2](#Fig2){ref-type="fig"}, we found that a short course of glucocorticosteroid treatment resulted in a significant decrease of S1P concentration in the blood (*P* \<0.02) and CSF (*P* \<0.05) of TBE patients. More precisely, before treatment S1P levels were 433.2 ± 19.2 nM and 2.29 ± 0.22 nM in plasma and CSF, respectively, and after treatment they were 370 ± 24.9 nM and 0.95 ± 0.21 nM in plasma and CSF, respectively. Average S1P concentration in plasma of TBE patients not treated with glucocorticosteroids remained stable (439.4 ± 21.0 nM versus 446 ± 35.8 nM). However, in the CSF of TBE subjects not treated with glucocorticosteroids, S1P concentration continued to increase during the course of the disease and was significantly higher (*P* \<0.05) in samples obtained during the second lumbar puncture performed 10 to 12 days after the first, compared to the samples taken during the first lumbar puncture, which was performed at the time of diagnosis (1.79 ± 0.39 nM versus 1.48 ± 0.23 nM)*.* This difference suggests an essential role of S1P in progression of these inflammatory processes. The initial S1P concentration in the CSF of subjects in poor general condition treated with glucocorticosteroids was higher compared to the initial S1P concentration in non-treated patients who were in better general condition. We did not observe significant changes in basic CSF parameters after glucocorticosteroid treatment (Table [1](#Tab1){ref-type="table"}). However, the decrease in pleocytosis, which is an indicator of inflammation, was greater in treated subjects. The mean difference between the first and second lumbar puncture (number of lymphocytes in 1 μl of CSF) was 29 and 17 in treated and non-treated patients, respectively.Figure 1**S1P concentration in blood plasma (A) and CSF (B) samples obtained from control (n =37) subjects and from patients with various inflammatory diseases of the CNS: MS (n =22), LNB (n =18), TBE (n =45).** \*Significantly different. Error bars represent standard error of the mean. S1P -- sphingosine -- 1-- phosphate, CSF -- cerebrospinal fluid, MS -- multiple sclerosis, LNB -- Lyme neuroborreliosis, TBE -- tick borne encephalitis.Figure 2**S1P concentration in blood plasma (A) and CSF (B) samples obtained from TBE patients.** TBE-I (n =24) and TBE + G-I (n =21) samples obtained before treatment from subjects not treated and treated with glucocorticosteroids, respectively. TBE-II (n =20) and TBE + G-II (n =19) samples obtained 10 to 12 days later from patients not treated and treated with glucocorticosteroids, respectively. \*Significantly different. Error bars represent standard error of the mean. S1P -- sphingosine -- 1-- phosphate, CSF -- cerebrospinal fluid, TBE -- tick borne encephalitis.

There is currently no specific treatment for TBE infection, and treatment with glucocorticosteroids is still used in the most severe cases in countries with a high prevalence of the disease \[[@CR27],[@CR28]\]. In the north-eastern part of Poland (region of Bialystok) the incidence of the disease is 5.1 to 13.1 out of 100,000, and patients from this region constitute more than 40% of all TBE cases reported in the whole country \[[@CR25]\]. A retrospective study conducted at the Departments of Infectious Diseases and Neuroinfections, Medical University of Białystok (Poland) included 687 patients diagnosed with TBE and hospitalized in this department between 1993 and 2008. About 60% (407 of 687) of them were given dexamethasone, with clinical improvement in most cases, and no serious side effects were observed \[[@CR25]\]. However, treatment with glucocorticosteroids is controversial \[[@CR29],[@CR30]\] and may lead to serious metabolic and circulatory complications. Therefore, this therapy should be reserved only for certain severe cases of the disease, in which probability of clinical benefit is higher than risk of serious adverse events. There is a need for new effective and safe medications.

Astrocytes are the most abundant cells in the brain \[[@CR31]\] and changes in their F-actin cytoskeleton organization occur during pro-inflammatory cytokine secretion \[[@CR32]\], as well as changes in the regulatory interface at the blood--brain barrier \[[@CR33]\]. Accordingly, following inflammatory stimuli, significant changes in astrocyte actin filament organization have been observed \[[@CR14],[@CR31]\]. Results from our cell culture studies indicate that factors interfering with S1P signaling affect astrocyte F-actin cytoskeletal organization. As shown in Figure [3](#Fig3){ref-type="fig"}A, a low concentration of S1P (1 μM) and recombinant human gelsolin (2 μM), added separately, did not have a dramatic effect on F-actin organization, but 1 μM S1P in combination with GSN produced a marked increase in the F-actin staining at the cytoplasmic margin (cortical F-actin), associated with a significant decrease of total F-actin (Figure [3](#Fig3){ref-type="fig"}B). In contrast, a high concentration (5 μM) of S1P produced a decrease in total F-actin concentration. Additionally, gaps comparable to the size of an astrocyte were observed in the monolayer after this treatment. These results may explain the severe blood-CSF barrier disruption in our TBE patients in whom the QALB (QALB = albumin concentration in CSF: albumin concentration in blood) ratio, an indicator of blood-CSF barrier function, was definitely above norm (norm for 40-year-old individuals is about 6.5) \[[@CR34]\]. At admission, patients treated and not treated with glucocorticosteroids had similar QALB ratios; 12.1 ± 1.4 and 11.3 ± 1.7, respectively. Indeed, there is evidence to suggest that weakening of the blood--brain barrier may precede, accelerate, or contribute to a number of neurodegenerative disorders, and that a gap formation may lead to changes in the blood-CSF barrier function \[[@CR35],[@CR36]\]. On the other hand, in the cell culture system, the effect of high S1P treatment was inhibited by co-treatment with gelsolin, 5 μM FTY720P, or a combination of gelsolin and FTY720P. Interestingly, treatment with 5 μM FTY720P alone caused a significant increase in F-actin, which was slightly inhibited by gelsolin.Figure 3**F-actin structure in rat astrocytes (confluent culture) treated with S1P, recombinant human plasma gelsolin and FTY720P, or their combination.** At 8 hours incubation the cells were fixed with 4% paraformaldehyde, permeabilized with Triton X-100 and F-actin was stained with Phalloidin-FITC. Arrows indicate gaps in astrocyte monolayers. Data from one representative experiment are shown **(A)**. **B** shows quantitative analysis of F-actin fluorescence in the astrocyte monolayer under treatment, indicated by numbers 1 to 10 in the left lower corner of each picture. \*Significantly different. Error bars represent standard error of the mean. S1P -- sphingosine -- 1-- phosphate, GSN -- recombinant human plasma gelsolin.

Astrocytes release a variety of cytokines in response to CNS infections and injuries \[[@CR37],[@CR38]\]. IL-6 is a pleiotropic pro-inflammatory cytokine produced by astrocytes that may also act as a trophic factor in the nervous system \[[@CR39]-[@CR41]\]. Mechanisms that regulate IL-6 expression require activation of p38 mitogen-activated protein kinases and depend on NF-κB transcriptional activity. Initiation of these pathways in astrocytes occurs when the PI3K-mTOR-AKT pathway is inhibited \[[@CR42]\]. As indicated by data shown in Figure [4](#Fig4){ref-type="fig"}, a statistically significant increase of IL-6 in blood and CSF was observed in samples collected from TBE subjects at the time of diagnosis, compared to controls (Figure [4](#Fig4){ref-type="fig"}). This observation confirmed our previous study \[[@CR43]\]. Moreover, in an animal model of TBE, significantly increased IL-6 mRNA was found, but only in mice susceptible to the infection. In the resistant strain, upregulation of IL-6 mRNA expression was not observed. These data suggest that excessive production of pro-inflammatory mediators, such as IL-6, may contribute to development of a more severe form of TBE \[[@CR44]\].Figure 4**IL-6 concentration in blood plasma (panel A) and cerebrospinal fluid (panel B) obtained from control (CNT, n =6) and TBE patients.** TBE-I (n =9) and TBE + G-I (n =10) samples obtained before treatment from subjects not treated and treated with glucocorticosteroids, respectively. TBE-II (n =9) and TBE + G-II (n =10) samples obtained 10 to 12 days later from patients not treated and treated with glucocorticosteroids, respectively. \*Significantly different. Error bars represent standard deviation of the mean. IL--6 -- interleukin 6, TBE -- tick borne encephalitis.

Our results indicate that S1P, but not GSN or FTY720-P, induced production of IL-6, and treatment with GSN or FTY720-P inhibited IL-6 release by rat astrocytes stimulated with S1P (Figure [5](#Fig5){ref-type="fig"}). These results suggest that the S1P pathway may partly govern the production of pro-inflammatory cytokines by astrocytes. Consequently, it is highly probable that the potential therapeutic effects of GSN (which has a significantly decreased concentration in the blood of TBE patients \[[@CR45]\]) and FTY720P might be caused by modulation of S1P-mediated activation of astrocytes in the CNS. It was recently reported that FTY720 exposure might regulate specific neuroinflammatory responses by desensitizing astrocytes to external S1P \[[@CR19]\]. Studies in experimental autoimmune encephalomyelitis using mice with conditionally deleted S1P(1) receptor from astrocytes indicate that one beneficial effect of FTY720P in this model occurs via downregulation of external receptors, which inhibits responses induced by the natural agonist. Another proposed effect of FTY720P on neuroinflammation is its ability to maintain persistent signaling in cells via internalized S1P(1) receptor resulting in functional responses that include suppressing intracellular calcium release \[[@CR19]\]. Further *in vivo* experiments with FTY720P would be required to demonstrate a causal role of S1P in the pathogenesis of TBE.Figure 5**S1P, recombinant human plasma gelsolin (rhGSN) and FTY720P prevent release of IL-6 from rat astrocytes.** IL-6 release from rat astrocytes 8 hours after addition of S1P, (rhGSN and FTY720P **(A)**. Decrease of IL-6 release from rat astrocytes activated with S1P (5 μM) in the presence of rhGSN (5 μM) and FTY720P (5 μM) **(B)**. \*Significantly different. Error bars represent standard deviation of the mean. IL--6 -- interleukin 6, S1P -- shingosine-1-phosphate

Conclusions {#Sec9}
===========

Acute CNS inflammation due to TBE virus infection is associated with an elevated S1P concentration in the blood and CSF of infected patients. In a cell culture system, the functions of astrocytes in an inflammatory state, induced by a high concentration of S1P, can be restored to their normal state by the administration of rhGSN, FTY720P, or their combination. This observation could be of clinical significance and might be useful for developing new treatments for pathological CNS conditions associated with rising concentrations of S1P in the blood and CSF, such as are produced by TBE.
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